GLP-1 Receptor Agonists Beyond Glycemic Control: Clinical Implications in Neurodegenerative Disease and Substance Use Disorders
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have expanded beyond glycemic control to include cardiovascular and renal risk reduction, with recent approval for reducing major adverse cardiovascular events in individuals with obesity or overweight and established cardiovascular disease. Increasing attention has...